GENFIT (EPA:GNFT) | WebDisclosure

Basculer en Français

10964	Companies
239965	Keywords
168732	Articles
129105	Press releases

Home
Companies
GENFIT

PRESS RELEASE

published on 06/10/2024 at 23:22, 2 years 3 months ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT achieves historic milestone with U.S. FDA accelerated approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis. Elafibranor tablets approved as first-in-class treatment, marking a significant development in rare liver disease treatment landscape

Primary Biliary Cholangitis GENFIT Ipsen Iqirvo FDA Accelerated Approval
BRIEF

published on 05/29/2024 at 22:15, 2 years 3 months ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Research Collaboration GENFIT ACLF EASL Congress Liver Disease
BRIEF

published on 05/29/2024 at 22:15, 2 years 3 months ago

GENFIT présentera ses dernières recherches sur l'ACLF au congrès EASL™ 2024

Collaboration En Recherche GENFIT ACLF Congrès De L'EASL Maladie Du Foie
PRESS RELEASE

published on 05/29/2024 at 22:10, 2 years 3 months ago

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GENFIT to present latest ACLF research at EASL Congress™ 2024, showcasing collaborative efforts with EF CLIF to advance understanding of ACLF pathophysiology and treatment approaches

Liver Diseases GENFIT ACLF Research EASL Congress 2024 EF CLIF Partnership
PRESS RELEASE

published on 05/29/2024 at 22:10, 2 years 3 months ago

GENFIT présentera ses dernières avancées dans l'ACLF à l'EASL Congress™ 2024
GENFIT présente ses avancées dans l'ACLF au congrès EASL 2024, détaillant un partenariat de recherche avec l'EF CLIF et des programmes de recherche dans l'ACLF, mettant en avant le potentiel de transformation du traitement

Recherche Traitement GENFIT ACLF EASL
BRIEF

published on 05/14/2024 at 22:15, 2 years 3 months ago

GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025

Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
BRIEF

published on 05/14/2024 at 22:15, 2 years 3 months ago

GENFIT annonce ses résultats financiers du premier trimestre 2024 et dispose d'une trésorerie disponible jusqu'à fin 2025

Industrie Biopharmaceutique Essais Cliniques Baisse Des Revenus Résultats Financiers De GENFIT Situation De Trésorerie
PRESS RELEASE

published on 05/14/2024 at 22:10, 2 years 3 months ago

GENFIT Reports First Quarter 2024 Financial Information
GENFIT reports Q1 2024 financial information showing cash position of €74.0 million and revenues of €1.1 million. Company expects cash to fund operations until Q4 2025

Financial Information Revenues Cash Position Q1 2024 GENFIT
PRESS RELEASE

published on 05/14/2024 at 22:10, 2 years 3 months ago

GENFIT : Information financière du premier trimestre 2024
GENFIT annonce sa situation de trésorerie au 31 mars 2024 et son chiffre d'affaires du premier trimestre 2024, avec des revenus en baisse par rapport à 2023

Chiffre D'affaires Biopharmaceutique Trésorerie Maladies Rares GENFIT

Accesswire

Published on 09/10/2026 at 22:25, 2 hours 21 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 7 hours ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 9 hours 26 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 9 hours 46 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 10 hours 9 minutes ago

Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 00:05, 40 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 45 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 2 hours 6 minutes ago

EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 2 hours 35 minutes ago

flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 2 hours 38 minutes ago

EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board

Les Echos

Published on 09/10/2026 at 19:30, 5 hours 16 minutes ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 5 hours 16 minutes ago

Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 6 hours 36 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 7 hours 1 minute ago

COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 7 hours 3 minutes ago

Déclaration d'actions et de droits de vote au 31.08.2026

View all LES ECHOS COMFI WIRE